Heavy metals testing sounds like a single checkbox, but in modern pharmaceutical quality it is a defined specification with its own limits and its own instrument. For a reconstituted, injected preparation it also happens to be one of the tests a standard purity certificate never performs. Understanding what the term means, and why the injectable route carries stricter limits, explains a real gap in most paperwork.
From "heavy metals" to elemental impurities
The phrase "heavy metals" is a legacy label. The current framework, the International Council for Harmonisation guideline ICH Q3D, controls what it calls elemental impurities. Q3D establishes permitted daily exposures (PDEs) for 24 elemental impurities, expressed in micrograms per day, across three routes of administration: oral, parenteral (injected) and inhalation. The elements are sorted into classes (1, 2A, 2B and 3) based on their toxicity and their likelihood of appearing in a drug product.
The four elements most people mean by "heavy metals," arsenic (As), cadmium (Cd), mercury (Hg) and lead (Pb), are Class 1. Q3D describes Class 1 as human toxicants with limited or no use in pharmaceutical manufacturing, whose presence typically comes from commonly used materials such as mined excipients, and which must be evaluated during the risk assessment across all potential sources and routes of administration. In other words, they are the elements you actively look for.
The permitted daily exposure framework
A PDE is a daily limit in micrograms, not a concentration. The same element carries a different PDE for each route because the body handles an ingested metal differently from an injected one. The Class 1 permitted daily exposures in Q3D(R1) Table A.2.1 are, in micrograms per day:
- Arsenic: 15 oral, 15 parenteral, 2 inhalation
- Cadmium: 5 oral, 2 parenteral, 3 inhalation
- Lead: 5 oral, 5 parenteral, 5 inhalation
- Mercury: 30 oral, 3 parenteral, 1 inhalation
Two things stand out. Lead is held to 5 micrograms per day on every route. Mercury's parenteral limit (3) is ten times lower than its oral limit (30). That pattern is not arbitrary.
Why parenteral limits are usually stricter
Q3D spells out the logic. Where route-specific parenteral safety data are absent, the parenteral PDE is derived from the oral PDE by dividing by a modifying factor tied to oral bioavailability:
- divide by 100 if oral bioavailability is <1%
- divide by 10 if it is 1% to <50%
- divide by 2 if it is 50% to <90%
- divide by 1 if it is >=90%
The principle is straightforward. A metal that is poorly absorbed from the gut is comparatively safe to swallow, because most of it never enters the bloodstream. Injection bypasses the gastrointestinal barrier entirely, so a poorly absorbed toxic metal that would mostly pass through an oral dose is delivered directly into circulation. The worse the oral absorption, the larger the correction, and the stricter the parenteral limit. This is why an injected preparation deserves closer scrutiny for elemental impurities than an oral one.
ICP-MS, the method that actually measures them
Detecting single-digit micrograms per day of a specific element requires atomic spectroscopy, not chromatography. USP General Chapter <233> (Elemental Impurities, Procedures) defines two instrumental procedures: Procedure 1 for elements amenable to inductively coupled plasma atomic (optical) emission spectroscopy (ICP-AES, also written ICP-OES), and Procedure 2 for elements amenable to inductively coupled plasma mass spectrometry (ICP-MS).
ICP-MS is the more sensitive of the two. USP <233> illustrates this with a worked example in which the instrument's linear dynamic range runs from 0.01 ng/mL to 0.1 ug/mL for lead and arsenic, low enough that the sample must be diluted to keep the reading inside the calibrated range. Sensitivity at that level is what lets a laboratory report an actual concentration for each element rather than a pass or fail impression.
Why the old "heavy metals" test disappeared
Until recently, many monographs used USP General Chapter <231>, Heavy Metals. It was officially omitted, with the omission aligned to an implementation date of 1 January 2018, coordinated with General Chapters <232> (Elemental Impurities, Limits) and <2232> (Elemental Contaminants in Dietary Supplements) and harmonized with ICH Q3D.
The reason it was retired matters for reading a certificate. The legacy <231> sulfide limit test measured metals "colored by sulfide ion." It used thioacetamide to generate sulfide, a Standard Lead Solution as reference, and a visual color comparison of the sample against the lead standard, with the limit expressed as a percentage by weight of lead. USP lists the substances that typically respond as lead, mercury, bismuth, arsenic, antimony, tin, cadmium, silver, copper and molybdenum. In other words, it was a non-specific, sulfide-reactive screen that returned a single summed impression, not an individual concentration for each element. A modern elemental impurities result by ICP-MS does the opposite: it quantifies each element separately against its own route-specific PDE.
Why a purity COA does not include heavy metals
This is the practical point. Elemental impurity control is a distinct specification, handled by dedicated chapters <232> (limits) and <233> (procedures) that require atomic spectroscopy (ICP-OES or ICP-MS). That is a fundamentally different technique from the HPLC and related chromatographic methods used to measure a peptide's organic purity and related substances. A chromatographic purity percentage describes how much of the organic material is the intended peptide versus organic impurities, which is a separate question from what a purity percentage means. It does not, and cannot, measure trace inorganic metal content.
So a certificate that reports 98 percent purity by HPLC is silent on arsenic, cadmium, mercury and lead. The numbers answer different questions. A purity result covers organic composition; elemental impurities require a separate ICP-MS run against ICH Q3D limits. This is exactly the omission that a testing perspective on research peptide safety and guidance on choosing a peptide testing lab both flag when describing what a certificate does and does not cover.
What a complete picture looks like
If elemental impurities matter for a given preparation, the evidence is a separate result: named elements measured by ICP-MS (or ICP-OES), reported as concentrations and compared against the appropriate ICH Q3D PDE (the parenteral column for anything injected). Q3D is a living standard; the current revision is Q3D(R2), reached through ICH Step 4 with R1 (2019) and R2 (2022) updates and adopted by regulators including the European Medicines Agency. A purity figure and an elemental impurities figure are complementary, not interchangeable, and only one of them speaks to the metals the phrase "heavy metals testing" was coined to describe.